Affitech licenses anti-VEGF candidates from partner Peregrine Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Affitech has exclusively licensed global rights to develop and commercialise product candidates from Peregrine Pharmaceuticals' preclinical anti-VEGF antibody portfolio, including the fully human antibody r84, which was discovered by Affitech and jointly developed by the companies under an ongoing collaboration.